CTLA-4, PD-1, LAG3, TIM3 and TIGIT display distinct vesicular distributions in murine T cells

被引：0
|
作者：
Lu, Jiahe [1 ,2 ]
Simonetti, Boris [1 ,3 ]
Veler, Alisa [1 ]
Cross, Stephen [1 ]
Ruan, Xiongtao [4 ]
Raj, Timsse [1 ]
Dowsey, Andrew [1 ]
Murphy, Robert F. [4 ]
Verkade, Paul [1 ]
Cullen, Pete [1 ]
Wuelfing, Christoph [1 ]
机构：
[1] Univ Bristol, Bristol, Avon, England
[2] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
[3] Charles River Labs, Bristol, Avon, England
[4] Carnegie Mellon Univ, Pittsburgh, PA 15213 USA
来源：
EUROPEAN JOURNAL OF IMMUNOLOGY | 2024年 / 54卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
1713 - P2.
引用
收藏
页码：1182 / 1182
页数：1
相关论文
共 50 条
  • [1] Expression of TIGIT, BTLA, LAG3, FCRL3 and CTLA-4 in Sezary Syndrome
    Anzengruber, Florian
    Ignatova, Desislava
    Eberle-Schlapfer, Tanja
    Chang, Yun-Tsan
    French, Lars
    Guenova, Emmanuella
    EUROPEAN JOURNAL OF CANCER, 2018, 101 : S5 - S5
  • [2] Breast Cancer Cells and PD-1/PD-L1 Blockade Upregulate the Expression of PD-1, CTLA-4, TIM-3 and LAG-3 Immune Checkpoints in CD4+ T Cells
    Saleh, Reem
    Toor, Salman M.
    Khalaf, Sarah
    Elkord, Eyad
    VACCINES, 2019, 7 (04)
  • [3] The Landscape of Immunotherapy in Advanced NSCLC: Driving Beyond PD-1/PD-L1 Inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, Vaccines)
    Andrea De Giglio
    Alessandro Di Federico
    Giacomo Nuvola
    Chiara Deiana
    Francesco Gelsomino
    Current Oncology Reports, 2021, 23
  • [4] The Landscape of Immunotherapy in Advanced NSCLC: Driving Beyond PD-1/PD-L1 Inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, Vaccines)
    De Giglio, Andrea
    Di Federico, Alessandro
    Nuvola, Giacomo
    Deiana, Chiara
    Gelsomino, Francesco
    CURRENT ONCOLOGY REPORTS, 2021, 23 (11)
  • [5] Expression of inhibitory receptors PD-1, CTLA-4, and Tim-3 by peripheral T cells during pregnancy
    Smetanenko, E. A.
    Khonina, N. A.
    Leplina, O. Yu.
    Tikhonova, M. A.
    Batorov, E. V.
    Pasman, N. M.
    Chernykh, E. R.
    BYULLETEN SIBIRSKOY MEDITSINY, 2022, 21 (03): : 87 - 95
  • [6] Roles of PD-1, Tim-3 and CTLA-4 in immunoregulation in regulatory T cells among patients with sepsis
    Gao, Dong-Na
    Yang, Zhi-Xiang
    Qi, Qing-Hui
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2015, 8 (10): : 18998 - 19005
  • [7] Immune Co-inhibitory Receptors PD-1, CTLA-4, TIM-3, LAG-3, and TIGIT in Medullary Thyroid Cancers: A Large Cohort Study
    Shi, Xiao
    Li, Cui-Wei
    Tan, Li-Cheng
    Wen, Shi-Shuai
    Liao, Tian
    Zhang, Yan
    Chen, Tong-Zhen
    Ma, Ben
    Yu, Peng-Cheng
    Lu, Zhong-Wu
    Qu, Ning
    Wang, Yu
    Shi, Rong-Liang
    Wang, Yu-Long
    Ji, Qing-Hai
    Wei, Wen-Jun
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2021, 106 (01): : 120 - 132
  • [8] TIGIT expression in renal cell carcinoma infiltrating T cells is variable and inversely correlated with PD-1 and LAG3
    Perales, Oscar
    Jilaveanu, Lucia
    Adeniran, Adebowale
    Su, David G.
    Hurwitz, Michael
    Braun, David A.
    Kluger, Harriet M.
    Schoenfeld, David A.
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2024, 73 (10)
  • [9] Cancer combination therapies by silencing of CTLA-4, PD-L1, and TIM3 in osteosarcoma
    Sorkhabi, Amin Daei
    Sarkesh, Aila
    Fotouhi, Ali
    Saeedi, Hossein
    Aghebati-Maleki, Leili
    IUBMB LIFE, 2022, 74 (09) : 908 - 917
  • [10] Immune Co-inhibitory Receptors CTLA-4, PD-1, TIGIT, LAG-3, and TIM-3 in Upper Tract Urothelial Carcinomas: A Large Cohort Study
    Jin, Shengming
    Shang, Zhi
    Wang, Wenwen
    Gu, Chengyuan
    Wei, Yu
    Zhu, Yu
    Yang, Chen
    Zhang, Tiantian
    Zhu, Yao
    Zhu, Yiping
    Wu, Junlong
    Ye, Dingwei
    JOURNAL OF IMMUNOTHERAPY, 2023, 46 (04) : 154 - 159
12345